Aptar Pharma acquires worldwide license for Orbital Dry Powder Inhaler from Pharmaxis for undisclosed amount; high payload Orbital technology delivers up to 400 mg of powders in divided doses without the need to reload

Sample article from our Tissue & Hygiene

August 10, 2022 (press release) –

Aptar Pharma Acquires Orbital™ Dry Powder Inhaler (DPI) Worldwide License. Will help Aptar Pharma meet growing global demand for safe and convenient administration of high dose treatments to the lungs.

Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced that it has acquired the worldwide rights to clinical stage drug developer Pharmaxis’ proprietary Orbital™ inhaler, a unique device designed to deliver high payload dry powder to the lungs.

The Orbital technology helps meet an increasing global need to deliver high doses of drugs, such as antibiotics, to the lungs and allows powder payloads of up to 400mg to be inhaled by patients in divided doses without the need to reload. This unique platform was originally developed as a life cycle extending product for the Pharmaxis cystic fibrosis drug Bronchitol® (mannitol).

Howard Burnett, Vice President Global Pulmonary Category, Aptar Pharma commented, “With this acquisition, Aptar Pharma is pleased to be building on our current expertise for the treatment of chronic conditions. As a recognized global leader in respiratory drug delivery devices and associated services, we now have a wider offering to meet our customer needs.”

Gary Phillips, CEO Pharmaxis added, “I am delighted that Aptar Pharma, who are one of the world’s foremost drug delivery device companies, have seen the potential in the Orbital technology. We look forward to them building on the technical evaluations carried out during the option period and delivering new product solutions that can benefit drug developers and patients. Today’s announcement is a further example of our strategy to generate non-dilutive cash from the mannitol respiratory business.”

This acquisition strengthens Aptar Pharma’s leadership in respiratory by offering a broader range of devices and services, from formulation to patient. Coupled with their formulation expertise at Nanopharm, Human Factors and patient onboarding at Noble, analytical services at Next Breath – all Aptar Pharma companies – as well as their Digital Health offering, Aptar Pharma is able to optimize device design, customize drug development and differentiate with improved compliance to provide their customers with a value-added finished product.

Read full Press Release here – Aptar Pharma Acquires Orbital™ DPI Global License. 

https://www.aptar.com/wp-content/uploads/2022/08/PR-August-4-2022-Aptar-Pharma-Acquires-Orbital-Global-License.pdf

 

Find out more about Orbital™ Dry Powder Inhaler (DPI) here.

https://www.aptar.com/products/pharmaceutical/dry-powder-inhaler-dpi-orbital/

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Chelsey Quick
Chelsey Quick
- VP Client Success -

We offer built-to-order tissue & hygiene coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.